Home > Insider Trading > Filing (0001144204-14-052791)

Filing Details

Accession Number:: 0001144204-14-052791
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-08-27 17:50:37
Reporting Period:: 2014-08-25

Filing Date:: 2014-08-27
Accepted Time:: 2014-08-27 17:50:37
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070336	Achillion Pharmaceuticals Inc	ACHN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1315082	Ra Capital Healthcare Fund Lp	20 Park Plaza, Suite 1200 Boston MA 02116	No	No	Yes	No
1346824	Ra Capital Management, Llc	20 Park Plaza, Suite 1200 Boston MA 02116	No	No	Yes	No
1384859	Peter Kolchinsky	20 Park Plaza, Suite 1200 Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value	Disposition	2014-08-25	226,200	$10.94	18,024,807	No	4	S	Indirect	See Footnotes
Common Stock, $0.001 Par Value	Disposition	2014-08-25	105,196	$11.01	17,919,611	No	4	S	Indirect	See Footnotes
Common Stock, $0.001 Par Value	Disposition	2014-08-26	1,347,639	$11.13	16,571,972	No	4	S	Indirect	See Footnotes
Common Stock, $0.001 Par Value	Disposition	2014-08-26	52,361	$11.16	16,519,611	No	4	S	Indirect	See Footnotes
Common Stock, $0.001 Par Value	Disposition	2014-08-26	250,000	$11.80	16,269,611	No	4	S	Indirect	See Footnotes
Common Stock, $0.001 Par Value	Disposition	2014-08-26	150,000	$11.78	16,119,611	No	4	S	Indirect	See Footnotes
Common Stock, $0.001 Par Value	Disposition	2014-08-26	312,867	$11.77	15,806,744	No	4	S	Indirect	See Footnotes
Common Stock, $0.001 Par Value	Disposition	2014-08-27	116,989	$11.75	15,689,755	No	4	S	Indirect	See Footnotes
Common Stock, $0.001 Par Value	Disposition	2014-08-27	150,100	$11.48	15,539,655	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Footnotes

The securities sold include 186,841 shares for RA Capital Healthcare Fund, L.P. (the "Fund") and 39,359 shares for an account owned by Blackwell Partners, LLC (the "Blackwell Account").
The securities sold include 86,892 shares for the Fund and 18,304 shares for an account owned by the Blackwell Account.
The securities sold include 1,113,150 shares for the Fund and 234,489 shares for an account owned by the Blackwell Account.
The securities sold include 43,250 shares for the Fund and 9,111 shares for an account owned by the Blackwell Account.
The securities sold include 206,500 shares for the Fund and 43,500 shares for an account owned by the Blackwell Account.
The securities sold include 123,900 shares for the Fund and 26,100 shares for an account owned by the Blackwell Account.
The securities sold include 258,248 shares for the Fund and 54,439 shares for an account owned by the Blackwell Account.
The securities sold include 116,989 shares for the Fund.
The securities sold include 150,100 shares for the Fund.
Following the transactions set forth on Table I above, 12,225,810 shares are held by the Fund, and 3,313,845 shares are held in the Blackwell Account.
RA Capital Management, LLC (the "Adviser") is the general partner of the Fund and the investment adviser of the Blackwell Account. Peter Kolchinsky is the sole manager of the Adviser. In their respective capacities, each of Mr. Kolchinsky and the Adviser may be deemed to beneficially own the reported securities.
Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of their respective pecuniary interests therein. The filing of this Form 4 shall not be construed as an admission that Mr. Kolchinsky or the Adviser is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of securities reported herein.